A combined mutant of glucosyl hydrolase and its preparation method and application
By constructing a combination mutant of glucosyl hydrolase, the problem of insufficient activity of β-glucosidase was solved, and the efficiency of converting ginseng saponin Rg1 into ginseng saponin F1 was significantly improved, and efficient saponin hydrolysis was achieved, which improved pharmacological activity and industrialization were improved. Utilize potential.
Patent Information
- Application Number
- CN202410606886.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-05-16
AI Technical Summary
In the prior art, β-glucosidase has insufficient activity and the reaction environment is difficult to meet the optimal conditions of natural enzymes, resulting in low utilization of plant saponins of the Pentatellite family with high glucose genus low in vivo, limiting their pharmacological activity and industry. .
Through three-dimensional protein structure prediction and molecular docking technology, glucosyl hydrolase combination mutants are constructed. Specifically, by introducing alanine mutations at specific sites of BglSK enzymes, the hydrophobicity and activity of the enzyme are improved, and mutants such as T137A/L508A are formed. N338A/L508A and V340A/L508A enhance their hydrolysis efficiency of ginseng saponin Rg1.
The mutant significantly improved the efficiency of converting ginsenoside Rg1 into ginsenoside F1, with hydrolysis efficiency of 10.44 times, 8.43 times and 9.34 times that of wild type, respectively. The enzymatic lysis time is shorter, and can catalyze compositions with different content ranges, which expands the Application scope.
Smart Images

Figure CN118325874B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to a glucose-syl hydrolase combination mutant and a preparation method and application thereof. Background Art
[0002] Plants of the Araliaceae family, especially ginseng, American ginseng and Panax notoginseng, have a long history of medicinal use due to their significant tonic effects. They have now become an important source of various health products, functional foods and cosmetics. Ginsenoside F1, with a molecular formula of C 36 H 62 O9, a rare saponin component of Araliaceae, is a metabolite of ginsenoside Rg1. In recent years, research on ginsenoside F1 has been further deepened. The results showed that ginsenoside F1 showed significant inhibitory effects on protecting UV-induced cell apoptosis and proliferation of skin melanoma cells, playing an anti-photoaging role. Compared with other rare saponins, ginsenoside F1 is also a pro-angiogenic agent, which can promote angiogenesis in vitro and in vivo, inhibit vascular leakage, and resist atherosclerosis, preventing vascular aging. In addition, ginsenoside F1 has a neuroprotective effect on aging human astrocytes and the adverse effects of high-fat diet on the brain, showing more significant biological activity than other rare saponins. At the same time, the beneficial effects of ginsenoside F1 can extend to protecting the brain from amyloid β-induced toxicity and preventing Alzheimer's disease. Recent studies have also shown that ginsenoside F1 can significantly improve mitochondrial function, protect telomeres and ultimately delay cell aging. Therefore, ginsenoside F1 has become a potential active substance for promoting healthy aging.
[0003] Ginsenoside F1 is usually formed by removing a molecule of glucose from ginsenoside Re or ginsenoside Rg1 by β-glucosidase. β-glucosidase can break the glycosidic bond formed by the reaction of alcohol hydroxyl and hemiacetal in an exo- or endo-cut manner, thereby effectively and directionally hydrolyzing natural active substances containing glucosides, such as ginsenosides. At present, the ginsenoside components of plants belonging to the Araliaceae family, such as Panax notoginseng, ginseng, and American ginseng, generally show a high degree of glycosylation of monomer saponins, resulting in low oral bioavailability in humans. Modern studies have shown that compared with prototype saponins, deglycosylated rare saponins show higher biological and pharmacological activities. Therefore, finding monomer enzymes or combined enzymes that can specifically hydrolyze a variety of large polar saponins is the key to solving the problem of efficient production and high-value utilization in the actual industrial application process. However, there are still large technical barriers for β-glucosidase with specific hydrolysis of ginsenosides in large-scale applications. The activity of natural β-glucosidase is insufficient, and its reaction environment is often difficult to meet the optimal conditions of natural enzymes. Summary of the invention
[0004] In order to overcome the shortcomings of the prior art, the present invention provides a glucosyl hydrolase mutant combination that can selectively convert ginsenoside Rg1 into ginsenoside F1 through bioinformatics techniques such as protein three-dimensional structure prediction and molecular docking with substrates, which can solve the problem of insufficient glucosidase activity.
[0005] In order to achieve the technical goal, the present invention is specifically implemented through the following technical solutions:
[0006] The first purpose of the present invention is to provide a glucosyl hydrolase combination mutant, wherein the glucosyl hydrolase mutant is a combination of threonine at position 137 and leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO:1 and mutated into alanine having a strong hydrophobic side chain and weak steric hindrance; or, a combination of asparagine at position 338 and leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO:1 and mutated into alanine having a strong hydrophobic side chain and weak steric hindrance; or, a combination of valine at position 340 and leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO:1 and mutated into alanine having a strong hydrophobic side chain and weak steric hindrance.
[0007] That is, the combined mutants are respectively mutated by combining the threonine at position 137, the asparagine at position 338, or the valine at position 340 and the leucine at position 508 of the BglSK enzyme as shown in the amino acid sequence of SEQ ID NO: 1 into alanine with a strong hydrophobic side chain and weak steric hindrance.
[0008] Furthermore, the threonine at position 137 and the leucine at position 508 of the BglSK enzyme are combined and mutated to alanine to obtain the combined mutant T137A / L508A, and the amino acid sequence is shown in SEQ ID NO:5; the asparagine at position 338 and the leucine at position 508 are combined and mutated to alanine to obtain the combined mutant N338A / L508A, and the amino acid sequence is shown in SEQ ID NO:7; the valine at position 340 and the leucine at position 508 of the BglSK are combined and mutated to alanine to obtain the combined mutant V340A / L508A, and the amino acid sequence is shown in SEQ ID NO:9.
[0009] Furthermore, the nucleotide sequence encoding the combined mutant T137A / L508A gene is shown as SEQ ID NO:6; the nucleotide sequence encoding the combined mutant N338A / L508A gene is shown as SEQ ID NO:8; and the nucleotide sequence encoding the combined mutant V340A / L508A gene is shown as SEQ ID NO:10.
[0010] Furthermore, the BglSK enzyme is derived from Sanguibacter keddieii, specifically, by codon optimizing the nucleotide sequence of the Sanguibacter keddieii β-glucosidase sequence D1BKC5 (sequence number ACZ20402 translated protein sequence; SEQ ID NO: 1), and the nucleotide sequence of the codon-optimized gene of the BglSK enzyme is shown in SEQ ID NO: 2.
[0011] The second object of the present invention is to provide a method for preparing the above-mentioned glucosyl hydrolase combination mutant, which can solve the problem of preparing high-activity glucosidase.
[0012] A method for preparing a glucosyl hydrolase combination mutant comprises the following steps:
[0013] Step 1: Connect the coding gene of the BglSK enzyme to be mutated into the plasmid to obtain a recombinant plasmid;
[0014] Step 2: Design and use site-directed mutagenesis primers, use the recombinant plasmid as a template for amplification, and obtain a mutant product by enzyme digestion; wherein the site-directed mutagenesis primer mutates the leucine at position 508 of the BglSK enzyme;
[0015] Step 3: Transform the mutant product into host cells and screen to obtain the mutant L508A;
[0016] Step 4: designing and using site-directed mutagenesis primers, using the recombinant L508A plasmid as a template for amplification, and obtaining a mutant product by enzyme digestion; wherein the site-directed mutagenesis primers mutate the threonine at position 137, the asparagine at position 338, or the valine at position 340 of the BglSK enzyme;
[0017] Step 5: Transform the mutant product into host cells, screen and induce the host cells to express and obtain the glucosyl hydrolase combination mutant.
[0018] Furthermore, the nucleotide sequence of the gene encoding the BglSK enzyme is shown in SEQ ID NO:2.
[0019] Further, in the step 2, the threonine at position 137 of the BglSK enzyme is mutated to alanine by upstream primers T137A-F and downstream primers T137A-R, the nucleotide sequence of the upstream primer T137A-F is shown in SEQ ID NO: 13, and the nucleotide sequence of the downstream primer T137A-R is shown in SEQ ID NO: 14; the asparagine at position 338 of the BglSK enzyme is mutated to alanine by upstream primers N338A-F and downstream primers N338A-R, the nucleotide sequence of the upstream primer N338A-F is shown in SEQ ID NO: 15, and the nucleotide sequence of the downstream primer N338A-R is shown in SEQ ID NO: 16; the valine at position 340 of the BglSK enzyme is mutated to alanine by upstream primers V340A-F and downstream primers V340A-R, and the nucleotide sequence of the upstream primer V340A-F is shown in SEQ ID NO: NO:17, and the nucleotide sequence of the downstream primer V340A-R is shown in SEQ ID NO:18; the leucine at position 508 of the BglSK enzyme is mutated to alanine by the upstream primers L508A-F and the downstream primers L508A-R, the nucleotide sequence of the upstream primer L508A-F is shown in SEQ ID NO:19, and the nucleotide sequence of the downstream primer L508A-R is shown in SEQ ID NO:20.
[0020] Furthermore, the host cell of the recombinant plasmid includes any one of Escherichia coli, Pichia pastoris and Saccharomyces cerevisiae.
[0021] The third object of the present invention is to provide the application of the above-mentioned glucosyl hydrolase combination mutant, which can solve the problem of preparing ginsenoside F1.
[0022] An application of a glucosyl hydrolase combination mutant, wherein the glucosyl hydrolase combination mutant is used for preparing ginsenoside F1.
[0023] Furthermore, the application catalyzes the conversion of ginsenosides Rg1 and Re into F1 through a glucoside combination mutant.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] 1. The glucosyl hydrolase mutant of the present invention has a short side chain with strong hydrophobicity and does not affect the substrate binding to hydrophobic amino acids. The combined mutants T137A / L508A, N338A / L508A, and V340A / L508A can promote the hydrolysis of ginsenoside Rg1 and effectively improve the efficiency of converting ginsenoside Rg1 to ginsenoside F1; the hydrolysis efficiency is 10.44 times, 8.43 times, and 9.34 times that of the wild type, respectively, and the enzymatic hydrolysis time is shorter;
[0026] 2. The preparation method of the glucosyl hydrolase mutant of the present invention uses computer-aided protein engineering enzyme molecule design to analyze the active pocket region of the β-glucosidase BglSK from Sanguibacter keddieii for molecular docking, and then constructs a mutant library through site-directed mutagenesis technology. The preparation method is accurate and has good effect;
[0027] 3. The glucosyl hydrolase mutant of the present invention can catalyze the conversion of ginsenoside Rg1 to prepare compositions containing ginsenoside F1 in different content ranges, and has a wide range of applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is the legend for the conversion of ginsenoside Rg1 into ginsenoside F1;
[0029] Figure 2 This is the simulation diagram of the molecular docking between BglSK enzyme and ginsenoside Rg1;
[0030] Figure 3 The AlphaFold2 protein three-dimensional structure prediction model of the BglSK enzyme wild type WT and its mutants L508A, T137A / L508A, N338A / L508A, V340A / L508A and F507A / L508A;
[0031] Figure 4 This is a diagram showing the hydrolysis efficiency of wild-type and mutant BglSK enzymes in converting ginsenoside Rg1 to generate ginsenoside F1;
[0032] Figure 5 This is the HPLC result of the reaction solution after whole-cell catalysis. DETAILED DESCRIPTION
[0033] Natural beta-glucosidase is not active enough, and its reaction environment is often difficult to meet the optimal conditions of natural enzymes. As related technologies such as molecular biology and genetic engineering gradually mature, protein sequences are edited and modified, which can strengthen the interpretation of enzyme catalysis mechanism and the design of guiding enzymes. Therefore, the present invention constructs a mutant library of glucosyl hydrolase through bioinformatics techniques such as molecular docking of protein and substrate, and provides a high-activity glucosyl hydrolase combination mutant to solve the problem of insufficient activity of beta-glucosidase.
[0034] First, the present invention provides a combined mutant of glucosyl hydrolase, wherein the combined mutant of the glucosyl hydrolase is a mutant in which the threonine at position 137 and the leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO:1 are mutated into alanine having a strong hydrophobic side chain and weak steric hindrance; or, the combined mutant of the asparagine at position 338 and the leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO:1 are mutated into alanine having a strong hydrophobic side chain and weak steric hindrance; or, the combined mutant of the valine at position 340 and the leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO:1 are mutated into alanine having a strong hydrophobic side chain and weak steric hindrance.
[0035] Furthermore, the threonine at position 137 and the leucine at position 508 of the BglSK enzyme are combined and mutated to alanine to obtain the combined mutant T137A / L508A, and the amino acid sequence is shown in SEQ ID NO:5; the asparagine at position 338 and the leucine at position 508 are combined and mutated to alanine to obtain the combined mutant N338A / L508A, and the amino acid sequence is shown in SEQ ID NO:7; the valine at position 340 and the leucine at position 508 of the BglSK are combined and mutated to alanine to obtain the combined mutant V340A / L508A, and the amino acid sequence is shown in SEQ ID NO:9.
[0036] After the 137th, 338th and 340th positions of the BglSK enzyme were mutated in combination with the 508th position, the hydrolysis efficiency was greatly improved compared with the wild-type β-glucosidase, and the hydrolysis efficiency of the combined mutant T137A / L508A was improved by more than 10 times.
[0037] Furthermore, the nucleotide sequence encoding the combined mutant T137A / 508A gene is shown in SEQ ID NO:6; the nucleotide sequence encoding the combined mutant N338A / 508A gene is shown in SEQ ID NO:8; and the nucleotide sequence encoding the combined mutant V340A / L508A gene is shown in SEQ ID NO:10.
[0038] Furthermore, the BglSK enzyme is derived from Sanguibacter keddieii, specifically, by codon optimizing the nucleotide sequence of the Sanguibacter keddieii β-glucosidase sequence D1BKC5 (sequence number ACZ20402 translated protein sequence; SEQ ID NO: 1), and the nucleotide sequence of the codon-optimized gene of the BglSK enzyme is shown in SEQ ID NO: 2.
[0039] Secondly, the present invention also provides a method for preparing the above-mentioned glucosyl hydrolase combination mutant, which can solve the problem of preparing high-activity glucosidase, comprising the following steps:
[0040] Step 1: Connect the coding gene of the BglSK enzyme to be mutated into the plasmid to obtain a recombinant plasmid;
[0041] Step 2: Design and use site-directed mutagenesis primers, use the recombinant plasmid as a template for amplification, and obtain a mutant product by enzyme digestion; wherein the site-directed mutagenesis primer mutates the leucine at position 508 of the BglSK enzyme;
[0042] Step 3: Transform the mutant product into host cells and screen to obtain the mutant L508A;
[0043] Step 4: designing and using site-directed mutagenesis primers, using the recombinant L508A plasmid as a template for amplification, and obtaining a mutant product by enzyme digestion; wherein the site-directed mutagenesis primers mutate the threonine at position 137, the asparagine at position 338, or the valine at position 340 of the BglSK enzyme;
[0044] Step 5: Transform the mutant product into host cells, screen and induce the host cells to express and obtain the glucosyl hydrolase combination mutant.
[0045] Furthermore, the nucleotide sequence of the gene encoding the BglSK enzyme is shown in SEQ ID NO:2.
[0046] Furthermore, in step 2, the leucine at position 508 of the BglSK enzyme is mutated to alanine by upstream primers L508A-F and downstream primers L508A-R, the nucleotide sequence of the upstream primers L508A-F is shown in SEQ ID NO: 19, and the nucleotide sequence of the downstream primers L508A-R is shown in SEQ ID NO: 20;
[0047] In the step 4, the threonine at position 137 of the BglSK enzyme is mutated to alanine by upstream primers T137A-F and downstream primers T137A-R, the nucleotide sequence of the upstream primer T137A-F is shown in SEQ ID NO: 13, and the nucleotide sequence of the downstream primer T137A-R is shown in SEQ ID NO: 14; the asparagine at position 338 of the BglSK enzyme is mutated to alanine by upstream primers N338A-F and downstream primers N338A-R, the nucleotide sequence of the upstream primer N338A-F is shown in SEQ ID NO: 15, and the nucleotide sequence of the downstream primer N338A-R is shown in SEQ ID NO: 16; the valine at position 340 of the BglSK enzyme is mutated to alanine by upstream primers V340A-F and downstream primers V340A-R, the nucleotide sequence of the upstream primer V340A-F is shown in SEQ ID NO: 17, and the nucleotide sequence of the downstream primer V340A-R is shown in SEQ ID NO: Shown in NO:18.
[0048] Finally, the present invention also provides the application of the above-mentioned glucosyl hydrolase combination mutant, which can solve the problem of preparing ginsenoside F1. The glucosyl hydrolase mutant is used to prepare ginsenoside F1.
[0049] Furthermore, the application catalyzes the conversion of ginsenosides Rg1 and Re into F1 through a glucoside mutant.
[0050] Below, the present invention is further described in conjunction with the accompanying drawings and specific embodiments. It is necessary to point out that the embodiments are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. In addition, it should be understood that after reading the content taught by the present invention, a person skilled in the art in this field can make some non-essential improvements and adjustments based on the content of the present invention described above, and these equivalent forms also fall within the scope defined by the claims attached to this application.
[0051] The following examples are experimental methods with specific conditions indicated. Conventional experimental conditions or experimental conditions recommended by the manufacturer are generally followed. Unless otherwise specified, the various reaction reagents involved in the examples can be purchased through commercial channels. For molecular biology experimental methods not specifically described in this example, please refer to the Molecular Cloning Experiment Guide.
[0052] Example 1 Molecular docking of the tertiary structure model of BglSK enzyme and ginsenoside Rg1
[0053] Combined with the deglycosylation mechanism of ginsenoside Rg1 into ginsenoside F1, as shown in Figure 1, the constructed three-dimensional structure model of BglSK enzyme was molecularly docked with the substrate ginsenoside Rg1. Figure 2As shown. The glucose group connected to the C6 position of ginsenoside Rg1 is located in the active pocket of the BglSK enzyme, while the rest of the structure of ginsenoside Rg1 is located on the surface of the enzyme. The β-D-pyranose glucose group connected to the glucose group connected to the C6 position of the parent ring of ginsenoside Rg1 has an obvious steric hindrance relationship with the pocket domain, including threonine at position 137, asparagine at position 338, valine at position 340, phenylalanine at position 507 and leucine at position 508. Prioritizing, leucine at position 508 was used as the core steric hindrance amino acid, and it was combined with the other four adjacent amino acid residues to be mutated to alanine. Based on the predicted three-dimensional structure of the protein, the activity of the mutant enzyme was further tested to explore the synergy of its site mutations.
[0054] Example 2 BglSK enzyme to be mutated and plasmid
[0055] The gene of Sanguibacter keddieii ACZ20402 was optimized for codon preference in E. coli, and the steps were as follows: the β-glucosidase gene of the nucleotide sequence of SEQ ID NO: 2 was connected to the pET-28a plasmid to obtain the recombinant plasmid pET-28a-BglSK; the plasmid was transformed into E. coli BL21 (DE3), and the recombinant strain was named BL21 (DE3) / pET-28a-BglSK. The amino acid sequence of the BglSK enzyme expressed by the recombinant enzyme strain is shown in SEQ ID NO: 1.
[0056] Example 3 Obtaining BglSK mutant strain
[0057] 1. Construction of mutant enzyme vector by whole plasmid PCR
[0058] Step 1. Extract a small amount of the recombinant plasmid pET-28a-BglSK;
[0059] Step 2. Design mutation primers. The primers include a 15 bp overlap region and a 15 bp extension region, wherein the mutation site is designed in the overlap region. The mutation site is a single-site mutation of Leu508, and the mutant amino acid is alanine with a strong hydrophobic side chain and weak steric hindrance;
[0060] Step 3. Perform full plasmid PCR amplification using plasmid pET-28a-BglSK as a template. The PCR system is shown in Table 1:
[0061] Table 1. Full plasmid PCR amplification system
[0062]
[0063] The primers Primer-F and Primer-R are PCR upstream primers and downstream primers designed accordingly according to different mutation sites. The specific primer information is shown in Table 2.
[0064] Table 2 Primers for PCR amplification of single point mutations in whole plasmid
[0065]
[0066] Primer pair L508A-F and L508A-R were used to obtain mutant enzyme L508A, the amino acid sequence of mutant enzyme L508A was shown in SEQ ID NO:3, and the nucleotide sequence of the encoding gene was shown in SEQ ID NO:4.
[0067] PCR amplification program: pre-denaturation at 98°C for 5 min; cycle setting: denaturation at 98°C for 15 s, annealing at 62°C for 30 s, extension at 72°C for 1.5 min, 30 cycles; final extension at 72°C for 10 min; after the reaction, the PCR product was recovered using a kit.
[0068] Step 4. Remove the template DNA by enzyme digestion, and perform enzyme digestion on the PCR recovered product. The enzyme digestion system is shown in Table 3:
[0069] Table 3 Enzyme digestion system of whole plasmid PCR product
[0070] QuickCut DpnⅠ 1μL PCR products ≤1 μg 10×QuickCut Buffer 3μL <![CDATA[ddH2O]]> Make up to 30 μL
[0071] The above enzyme digestion system was placed in a 37°C metal bath for digestion for 1 hour. After the reaction was completed, the enzyme digestion product was recovered using a kit.
[0072] 2. Sequencing to verify whether the mutant enzyme strain is successfully constructed
[0073] The above enzyme digestion products were transformed into Escherichia coli BL21 (DE3) competent cells, inverted and cultured overnight at 37°C, and the pseudo-positive transformants were picked for sequencing verification, and the mutant enzyme expression strain BL21 (DE3) / pET-28a-BglSK-L508A strain was successfully obtained.
[0074] Example 4 Whole-cell catalytic reaction of BglSK and its mutant enzyme L508A
[0075] 1. Induction of BglSK recombinant strains and mutant enzyme recombinant strains and preparation of whole cell enzyme solution
[0076] Step 1. Take BL21 (DE3) / pET-28a-BglSK, BL21 (DE3) / pET-28a-BglSK-L508A strains, and streak them on LB plates containing Kan (100 μg / mL) for activation. After inverted culture at 37 ° C overnight, pick a single colony and inoculate it into 1 mL of LB liquid medium containing Kan, and culture it at 37 ° C, 200 r / min shaking for 12-16 hours. Inoculate the overnight cultured seed liquid into 20 mL of fresh LB liquid medium containing Kan according to the inoculation amount of 1%, and culture it at 37 ° C, 200 r / min shaking for 2-3 hours until OD600 is 0.6-0.8, add IPTG with a final concentration of 0.1 mM, put the culture solution at 20 ° C, and culture it at 150 r / min shaking for 18 hours to induce protein expression.
[0077] Step 2. After protein induction, collect the cells by centrifugation at 5000 rpm for 5 min at 4°C. Wash the cells once with phosphate buffer (pH 7.0), then add an appropriate amount of phosphate buffer (pH 7.0) according to the wet weight of the cells to resuspend the cells to obtain a cell suspension with a whole cell concentration of 50 mg / mL. All operations were performed on ice or at 4°C.
[0078] 2. Whole Cell Response
[0079] The whole cell suspension of the BglSK wild-type enzyme WT and the mutant L508A enzyme obtained in the above experiment was used as the enzyme solution, and the reaction system shown in Table 4 was prepared:
[0080] Table 4 Whole cell reaction solution system
[0081]
[0082] The whole cell reaction system was reacted at 40°C for 1 hour. After the reaction was completed, 1 volume of methanol was added to terminate the reaction, and the cells were removed by centrifugation at 12000 rpm for 1 minute after sufficient vortexing. The reaction product was filtered through a 0.45 μm organic filter head and then tested by HPLC to calculate the conversion rate (normalization method).
[0083] 3. Detection method of ginsenoside F1
[0084] HPLC was used for quantitative analysis of ginsenoside F1, and the chromatographic conditions were as follows:
[0085] High performance liquid chromatograph: Agilent 1100 Series
[0086] Column: Diamonsil® 5 μm C18 (250 mm x 4.6 mm x 5 μm)
[0087] Detector: VWD detector, detection wavelength 208nm
[0088] Mobile phase ratio and elution conditions: flow rate 1mL / min; column temperature 30°C; injection volume 10μL; gradient elution system as shown in Table 5:
[0089] Table 5 HPLC gradient elution system
[0090]
[0091] 4. Results Analysis
[0092] The results of the whole cell catalytic reaction are as follows Figure 4 and Figure 5 As shown. Under the reaction conditions of 40°C, pH 7.0 and reaction time of 1h, the hydrolysis efficiency of the product ginsenoside F1 produced by the wild-type WT BglSK enzyme reaction was only 2.13%, while the hydrolysis efficiency of the product ginsenoside F1 produced by the mutant L508A reaction was increased to 10.49%, which was 4.93 times that of the wild-type.
[0093] Example 5 Iterative Combinatorial Mutant Construction and Whole-Cell Catalysis
[0094] 1. Iterative Combinatorial Mutant Construction
[0095] According to the results of Example 4, after the leucine site at position 508 of the BglSK enzyme was mutated to alanine with a hydrophobic side chain, the hydrolysis efficiency of the substrate was significantly improved. Therefore, using the mutant L508A as the initial template, iterative site-directed mutations were performed on the threonine at position 137, the asparagine at position 338, the valine at position 340 and the phenylalanine at position 507 to alanine with the same hydrophobic side chain, and a combined mutation library of Thr137 / Leu508, Asn338 / Leu508, Val340 / Leu508 and Phe507 / Leu508 was constructed to increase the hydrophobic attraction of the active pocket to the substrate ginsenoside Rg1 and expand the binding pocket volume, thereby increasing the interaction between the BglSK enzyme and the substrate ginsenoside Rg1.
[0096] The steps of constructing mutants and the whole-cell catalysis step are the same as those in Examples 3 and 4, and the primers used are shown in Table 6 below.
[0097] Table 6 Combined mutation full plasmid PCR amplification primers
[0098]
[0099] The first round mutant enzyme L508A was used as a plasmid template, and the primer pair T137A-F and T137A-R were used to obtain the mutant enzyme T137A / L508A, and the amino acid sequence of the mutant enzyme T137A / L508A was SEQ ID NO: 5; the primer pair N338A-F and N338A-R were used to obtain the mutant enzyme N338A / L508A, and the amino acid sequence of the mutant enzyme N338A / L508A was SEQ ID NO: 7; the primer pair V340A-F and V340A-R were used to obtain the mutant enzyme V340A / L508A, and the amino acid sequence of the mutant enzyme V340A / L508A was SEQ ID NO:9; using the wild-type WT recombinant plasmid as a template, the primer pair F507A / L508A-F and F507A / L508A-R were used to obtain the mutant enzyme F507A / L508A, and the amino acid sequence of the mutant enzyme F507A / L508A was SEQ ID NO:11.
[0100] 2. Iterative Combination Mutation Whole Cell Results
[0101] The reaction conditions were 40℃, pH 7.0, and the reaction time was 1h. The results of the whole-cell catalytic reaction were as follows: Figure 4 and Figure 5 The hydrolysis efficiency of the product ginsenoside F1 produced by the BglSK enzyme combined mutant F507A / L508A was 9.28%, which was 1.21% lower than that of the single point mutant L508A. However, the hydrolysis efficiency of the product ginsenoside F1 was increased to 22.24%, 17.96% and 19.89% by the combined mutants T137A / L508A, N338A / L508A and V340A / L508A, respectively, which were 1.21% lower than that of the single point mutant L508A. The iterative combination mutants T137A / L508A, N338A / L508A and V340A / L508A greatly improved the hydrolysis efficiency of ginsenoside Rg1 converted into ginsenoside F1 by deglycosylation, among which the hydrolysis efficiency of the combined mutant T137A / L508A showed an increase of more than 10 times compared with the wild type WT.
[0102] Example 6 Small-scale reaction of ginsenoside F1
[0103] According to the results of the iterative combined mutation of the BglSK enzyme in Example 5, the combined mutant enzyme strain T137A / L508A was selected as the fermentation strain, and the strain β-glucosidase protein induction and whole cell preparation method in Example 4 were referred to, and the reaction time was extended to 12 h to test the whole cell catalytic efficiency of converting ginsenoside Rg into ginsenoside F1. The liquid phase test results of ginsenoside F1 are as follows Figure 5 As shown, after the reaction time was extended to 12 h, the hydrolysis efficiency of the combined mutant T137A / L508A was as high as 98.29%, and no reaction by-products were generated during the catalytic process, indicating good specificity.
[0104] In summary, it can be seen that the present invention improves the activity of β-glucosidase based on steric hindrance, constructs a mutant library of glucosyl hydrolase, simulates the three-dimensional structure of wild-type β-glucosidase through computer-assisted protein and molecular visualization, and performs molecular docking with the substrate. Through molecular docking, the conformational relationship between the enzyme and the substrate is accurately predicted, and the relevant targets are efficiently obtained, thereby reducing the capacity of the mutant library. Through this site-directed mutagenesis technology, based on the understanding of the relationship between protein structure and function, the protein is purposefully designed and modified to give a predicted protein structure - with leucine at position 508 as the core steric hindrance amino acid, and it is combined with the remaining 4 adjacent amino acid residues to mutate to alanine, and then based on genetic engineering, the predicted protein three-dimensional structure is synthesized, the mutant enzyme activity is tested, and the site mutation synergy is explored. The verification results show that the hydrolysis efficiency of the product ginsenoside F1 is increased to 22.2 by the reaction of the combined mutants T137A / L508A, N338A / L508A and V340A / L508A. 4%, 17.96% and 19.89%, and their hydrolysis efficiencies were 2.12 times, 1.71 times and 1.90 times that of the single point mutant L508A, respectively, and their hydrolysis efficiencies were 10.44 times, 8.43 times and 9.34 times that of the wild type, respectively. The iterative combination mutants T137A / L508A, N338A / L508A and V340A / L508A greatly improved the hydrolysis efficiency of ginsenoside Rg1 converted into ginsenoside F1 by deglycosylation, among which the hydrolysis efficiency of the combined mutant T137A / L508A showed an increase of more than 10 times compared with the wild type WT.
[0105] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0106] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A glucosyl hydrolase combination mutant, characterized in that: The glucosyl hydrolase mutant is a mutant in which the threonine at position 137 and the leucine at position 508 of the BglSK enzyme with an amino acid sequence as shown in SEQ ID NO: 1 are mutated into alanine having a strongly hydrophobic side chain and weak steric hindrance; Or the asparagine at position 338 and the leucine at position 508 of the BglSK enzyme whose amino acid sequence is shown in SEQ ID NO: 1 are mutated in combination to alanine having a strongly hydrophobic side chain and weak steric hindrance; Or the combination of valine at position 340 and leucine at position 508 of the BglSK enzyme with an amino acid sequence as shown in SEQ ID NO: 1 is mutated to alanine having a strongly hydrophobic side chain and weak steric hindrance.
2. The method for preparing the combined mutant of glucosyl hydrolase according to claim 1, characterized in that: The following steps are involved: Step 1: Connect the coding gene of the BglSK enzyme to be mutated into the plasmid to obtain a recombinant plasmid; Step 2: Design and use site-directed mutagenesis primers, use the recombinant plasmid as a template for amplification, and obtain a mutant product by enzyme digestion; wherein the site-directed mutagenesis primer mutates the leucine at position 508 of the BglSK enzyme to alanine; Step 3: Transform the mutant product into host cells and screen to obtain the positive mutant L508A; Step 4: designing and using site-directed mutagenesis primers, using the recombinant L508A plasmid as a template for amplification, and digesting to obtain mutant products; wherein the site-directed mutagenesis primers mutate the threonine at position 137, the asparagine at position 338, or the valine at position 340 of the BglSK enzyme to alanine; Step 5: Transform the mutant product into a host cell, and induce the host cell to express to obtain a glucosyl hydrolase combination mutant.
3. The method for preparing a glucosyl hydrolase combination mutant according to claim 2, characterized in that: The nucleotide sequence of the gene encoding the BglSK enzyme is shown in SEQ ID NO:
2.
4. The method for preparing the combined mutant of glucosyl hydrolase according to claim 2, characterized in that: The threonine at position 137 of the BglSK enzyme was mutated to alanine by upstream primers T137A-F and downstream primers T137A-R. The nucleotide sequence of the upstream primers T137A-F is shown in SEQ ID NO: 13, and the nucleotide sequence of the downstream primers T137A-R is shown in SEQ ID NO: 14; The asparagine at position 338 of the BglSK enzyme was mutated to alanine by upstream primers N338A-F and downstream primers N338A-R. The nucleotide sequence of the upstream primer N338A-F is shown in SEQ ID NO: 15, and the nucleotide sequence of the downstream primer N338A-R is shown in SEQ ID NO: 16; The valine at position 340 of the BglSK enzyme was mutated to alanine by upstream primers V340A-F and downstream primers V340A-R. The nucleotide sequence of the upstream primer V340A-F is shown in SEQ ID NO: 17, and the nucleotide sequence of the downstream primer V340A-R is shown in SEQ ID NO: 18; The leucine at position 508 of the BglSK enzyme was mutated to alanine by upstream primers L508A-F and downstream primers L508A-R. The nucleotide sequence of the upstream primer L508A-F is shown in SEQ ID NO: 19, and the nucleotide sequence of the downstream primer L508A-R is shown in SEQ ID NO:
20.
5. The method for preparing the combined mutant of glucosyl hydrolase according to claim 2, characterized in that: The host cell is any one of Escherichia coli, Pichia pastoris and Saccharomyces cerevisiae.
6. The use of the combined mutant of glucosyl hydrolase according to claim 1, characterized in that: The glucosyl hydrolase mutant is used for catalytic conversion of ginsenosides Rg1 and Re to prepare ginsenoside F1.
